Phaseline

Targets › PP65

PP65: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on PP65, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Floridapp65 RNA loaded lipid particles (DP1)
mRNA vaccine encoding pp65 antigen in lipid nanoparticles
PP65Phase 1Recurrent GlioblastomaDec 2026

Conditions

Recurrent Glioblastoma (2)

Modalities

protein or peptide (1)

Companies

University of Florida (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.